These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 32404341)
21. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline. Bugatti S; De Stefano L; Bobbio-Pallavicini F; Montecucco C RMD Open; 2020 Oct; 6(3):. PubMed ID: 33087414 [No Abstract] [Full Text] [Related]
22. No Systemic Lupus Erythematosus with COVID-19 in Hong Kong: The Effect of Masking? So H; Mak JWY; Tam LS J Rheumatol; 2020 Oct; 47(10):1591. PubMed ID: 32482653 [No Abstract] [Full Text] [Related]
23. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Loarce-Martos J; García-Fernández A; López-Gutiérrez F; García-García V; Calvo-Sanz L; Del Bosque-Granero I; Terán-Tinedo MA; Boteanu A; Bachiller-Corral J; Vázquez-Díaz M Rheumatol Int; 2020 Dec; 40(12):2015-2021. PubMed ID: 32945944 [TBL] [Abstract][Full Text] [Related]
24. Dermatomyositis during COVID-19 Pandemic (A Case Series): Is there a Cause Effect Relationship? Gokhale Y; Patankar A; Holla U; Shilke M; Kalekar L; Karnik ND; Bidichandani K; Baveja S; Joshi A J Assoc Physicians India; 2020 Nov; 68(11):20-24. PubMed ID: 33187031 [TBL] [Abstract][Full Text] [Related]
25. Incidence of COVID-19 in an Italian cohort of patients with systemic lupus erythematosus: an observational survey. Fasano S; Ciccia F Clin Exp Rheumatol; 2021; 39 Suppl 128(1):13. PubMed ID: 33338005 [No Abstract] [Full Text] [Related]
26. Venous thrombosis in a systemic lupus erythematosus patient with antiphospholipid antibodies coinciding with mild Covid-19. Aguirre-Alastuey ME; Suárez-Díaz S; Rodríguez-Jerez F; Coto-Hernández R; Caminal-Montero L Lupus; 2021 Jan; 30(1):172-174. PubMed ID: 33092468 [No Abstract] [Full Text] [Related]
27. Hydroxychloroquine blood assay as a marker of nonadherence in patients with systemic lupus erythematosus: comment on the article by Koneru et al. Costedoat-Chalumeau N; Amoura Z; Marra D; Piette JC Arthritis Rheum; 2008 Jan; 59(1):153; author reply 153-4. PubMed ID: 18163410 [No Abstract] [Full Text] [Related]
28. Potential effects of cyclosporin A on coronary vasomotor function in young patients with systemic lupus erythematosus: comment on the article by Hirata et al. Korkmaz C Arthritis Rheum; 2008 Jan; 58(1):330-1; author reply 331. PubMed ID: 18163479 [No Abstract] [Full Text] [Related]
30. Letter to the Editor: Comment on Mulder J et al. (2021) indirect immunofluorescence for detecting anti-neuronal autoimmunity in CSF after COVID-19 - possibilities and pitfalls. Franke C; Prüss H Brain Behav Immun; 2021 May; 94():475. PubMed ID: 33639240 [No Abstract] [Full Text] [Related]
31. Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient. Shayestehpour M; Zamani B J Med Virol; 2021 May; 93(5):2599. PubMed ID: 33527457 [No Abstract] [Full Text] [Related]
32. Systemic lupus, immunosuppressives, COVID-19 vaccination, and antibody response: comment on the article by Petri et al. Kleebayoon A; Wiwanitkit V Arthritis Care Res (Hoboken); 2023 Oct; 75(10):2224-2225. PubMed ID: 36861888 [No Abstract] [Full Text] [Related]
33. The rarity of antinuclear antibody negativity in systemic lupus erythematosus: comment on the article by Merrill et al. Major GA Arthritis Rheum; 2011 Apr; 63(4):1157-8; author reply 1158. PubMed ID: 21452333 [No Abstract] [Full Text] [Related]
34. Are patients with systemic lupus erythematosus more prone to result false-positive for SARS-CoV2 serology? Elefante E; Tani C; Zucchi D; Signorini V; Ferro F; Mosca M Clin Exp Rheumatol; 2020; 38(3):577. PubMed ID: 32456766 [No Abstract] [Full Text] [Related]
35. Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis. Spinelli FR; Ceccarelli F; Di Franco M; Conti F Ann Rheum Dis; 2021 Jan; 80(1):e9. PubMed ID: 32366521 [No Abstract] [Full Text] [Related]
36. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Ramos-Casals M; Díaz-Lagares C; Khamashta MA Arthritis Rheum; 2009 Sep; 61(9):1281-2. PubMed ID: 19714598 [No Abstract] [Full Text] [Related]
37. Rheumatic diseases in intensive care unit patients with COVID-19. Moiseev S; Avdeev S; Brovko M; Yavorovskiy A; Novikov PI; Umbetova K; Akulkina L; Tsareva N; Fomin V Ann Rheum Dis; 2021 Feb; 80(2):e16. PubMed ID: 32434823 [No Abstract] [Full Text] [Related]
38. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Moiseev S; Avdeev S; Brovko M; Novikov P; Fomin V Ann Rheum Dis; 2021 Feb; 80(2):e19. PubMed ID: 32317315 [No Abstract] [Full Text] [Related]
39. Corticosteroids in preventing severe lupus flares: do all patients have the same risk? Comment on the article by Tseng et al. Callejas-Rubio JL; Rios-Fernández R; Tomás-Jiménez C; Ortego-Centeno N Arthritis Rheum; 2007 Jun; 56(6):2098-9; author reply 2099. PubMed ID: 17530655 [No Abstract] [Full Text] [Related]
40. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Conticini E; Bargagli E; Bardelli M; Rana GD; Baldi C; Cameli P; Gentileschi S; Bennett D; Falsetti P; Lanzarone N; Bellisai F; Barreca C; D'Alessandro R; Cantarini L; Frediani B Ann Rheum Dis; 2021 Feb; 80(2):e14. PubMed ID: 32414804 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]